Emerging research suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a significant advancement for obesity treatment. Initial human investigations have indicated considerable losses in visceral tissue, possibly exceeding other body composition medications . Despite this,